Manufacturing Arrangements. AngioDynamics agrees that it will continue to manufacture the products currently being manufactured for E-Z-EM at the respective prices currently charged for such products. E-Z-EM agrees to use all commercially reasonable efforts to engage a new manufacturer for such products (or comparable products) on or prior to December 31, 2004, and AngioDynamics agrees to assist and cooperate (at E-Z-EM's expense) with E-Z-EM's change in manufacturer for the aforementioned products. If the change in manufacturer for the products has not occurred by December 31, 2004, then E-Z-EM and AngioDynamics hereby agree that the prices for such products shall be increased so as to result in AngioDynamics achieving a gross margin of 50% on each such product. Ordering quantities shall be at the sole discretion of E-Z-EM; however, unless E-Z-EM orders lesser amounts of such products, AngioDynamics shall manufacture for E-Z-EM an amount of such products sufficient to sell to E-Z-EM an amount of such products consistent with (but subject to normal yearly variances) the amount sold to E-Z-EM in calendar 2003. The obligations of AngioDynamics hereunder shall terminate upon the earlier of either (i) 60 days after E-Z-EM gives notice to AngioDynamics that E-Z-EM no longer requires such manufacturing services or (ii) in the absence of a mutual agreement to the contrary, December 31, 2005.
Manufacturing Arrangements. Debiopharm shall provide contact information include primary contact name, email address and telephone number and also shall promptly provide such introductions to contract manufacturing organizations and other vendors identified in Exhibit C hereto as Curis may request during the Transition Period, and shall deliver to each such vendor such written notices and authorizations as may be necessary for such vendor to disclose and provide to Curis, and for Curis to access and use, the respective agreement between Debiopharm and such vendor, all data and results of the services performed by such vendor on behalf of Debiopharm with respect to Compound or Product (“Debio 0932 Services”), including, without limitation, raw data, documentation, batch records, source documents and reports regarding the Debio 0932 Services, and all Compound and Product material in such vendor’s possession.
Manufacturing Arrangements
